# US 10,946,049 B2 · Use of gram negative species to treat atopic dermatitis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,946,049 B2
- Document ID: US10946049B2
- Status: Granted
- Kind: B2
- Application number: 16/522,333
- Filed: 2019-07-25
- Published: 2019-12-19
- Granted: 2021-03-16
- Earliest claimed: 2016-04-19
- Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services
- Applicants: The United States of America, AS Represented By the Secretary, Department of Health and Human Services
- Inventors: Ian Antheni Myles; Sandip K. Datta
- Web page: https://patentgrep.com/patent/US10946049B2

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 9/0014: {Skin, i.e. galenical aspects of topical compositions (non-active ingredients are additionally classified in A61K47/00; A61K9/0009, A61K9/0021, A61K9/7015, A61K9/7023 take precedence; cosmetic preparations A61K8/00, A61Q; preparations for wound dressings or bandages A61L26/00)}
- A61K 9/06: Ointments; Bases therefor; {Other semi-solid forms, e.g. creams, sticks, gels (composition of ointments, creams or gels A61K47/00)}
- A61P 17/04: Antipruritics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Pharmaceutical compositions are disclosed that includes a therapeutically effective amount of a purified viable Gram negative bacteria and a pharmaceutically acceptable carrier. The pharmaceutical compositions are formulated for topical administration. Methods of treating atopic dermatitis using these pharmaceutical compositions are also disclosed.

## Claims

### Claim 1

A pharmaceutical composition, wherein the pharmaceutical composition comprises:
at least one strain of Roseomonas mucosa, wherein the at least one strain of Roseomonas mucosa is a viable, skin commensal organism present in an amount sufficient for reducing growth of Staphylococcus aureus on skin of a subject in need thereof, and wherein the pharmaceutical composition is formulated in a topical dosage form selected from the group consisting of a cream, gel, foam, ointment, and a lotion.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein the at least one strain of Roseomonas mucosa comprises at least two strains of Roseomonas mucosa.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein the at least one strain of Roseomonas mucosa comprises three strains of Roseomonas mucosa.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier.

### Claim 5 (depends on 4)

The pharmaceutical composition of claim 4, wherein the pharmaceutically acceptable carrier comprises sucrose.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the at least one strain of Roseomonas mucosa is purified.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the at least one strain of Roseomonas mucosa is present in an amount of 104 to 1012 colony forming units.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is contained within a spray bottle.